Observational studyCancer imaging : the official publication of the International Cancer Imaging Society2025
3 Tesla stack-of-stars echo unbalanced T1 relaxation-enhanced steady-state MRI for brain tumor imaging: post-contrast comparison with MPRAGE.
Observational study in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study compared the image quality and diagnostic utility of stack-of-stars echo-unbalanced T1 relaxation-enhanced steady-state (SOS echo-uT1RESS) with the widely used magnetization-prepared rapid gradient-echo (MPRAGE) sequence in brain tumor imaging.
methodsIn this prospective, two-center observational study, each participant underwent 3T contrast-enhanced MRI of the brain with both standard MPRAGE and prototype SOS echo-uT1RESS sequences. Lesion size, contrast-to-noise ratio (CNR), and tumor-to-brain contrast were quantitatively analyzed. Overall image quality, lesion conspicuity, and image artifacts were scored on a 4-point Likert scale, while diagnostic performance and assessment of the vascular and dural involvement were compared side-by-side by three readers.
resultsThirty-four adult patients (mean age, 64 years ± 13 [SD], 12 men) with known brain tumors (N = 6 intra-axial primary tumors; N = 14 intra-axial metastases; N = 14 extra-axial tumors) were enrolled in this study. There was no significant difference in CNR between MPRAGE and SOS echo-uT1RESS (29.4 ± 21.4 vs. 28.2 ± 16.5, respectively; p = 0.80, r = 0.03). SOS echo-uT1RESS demonstrated a 1.8-fold improvement in tumor-to-brain contrast compared with MPRAGE (0.7 ± 0.4 vs. 0.4 ± 0.3, respectively; p < 0.001, r = 0.81). While overall image quality and image artifacts were similar for both sequences, SOS echo-uT1RESS showed improved lesion conspicuity (p < 0.001, r = 0.51) and improved diagnostic performance (p < 0.001, r = 0.53), particularly for small metastases.
conclusionSOS echo-uT1RESS enhanced lesion visibility, achieving approximately a 1.8-fold improvement in tumor-to-brain contrast compared to MPRAGE, although this finding may reflect both sequence properties and timing-related effects. The sequence maintained comparable overall image quality and robustness, making it a promising tool for brain tumor imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.